News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Carl Ola Landgren: With Minimal Residual Disease (MRD) as an early endpoint for accelerated approval of new multiple myeloma drugs, patients access to new therapies will be much quicker
Photo taken from Carl Ola Landgren/Twitter
Apr 26, 2024, 14:15

Carl Ola Landgren: With Minimal Residual Disease (MRD) as an early endpoint for accelerated approval of new multiple myeloma drugs, patients access to new therapies will be much quicker

Carl Ola Landgren, Chief of the Myeloma Division and Translational Clinical Oncology Program at Sylvester Comprehensive Cancer Center, shared a post on X/Twitter:

“With Minimal Residual Disease (MRD) as an early endpoint for accelerated approval of new multiple myeloma drugs, patients’ access to new therapies will be much quicker.

Instead of waiting for 10-15 years, new drugs can be available in 3-5 years. Here is how it works.”

Source: Carl Ola Landgren/X

 

cancer Carl Ola Landgren MRD multiple myeloma Myeloma OncoDaily Oncology Sylvester Comprehensive Cancer Center Translational Clinical Oncology With Minimal Residual Disease
Special Coverage
Voices
Aug 15, 2025, 15:26
Team Survivor Northwest Marks 30 Years of Fitness and Support for Women Cancer Survivors
Voices
Aug 15, 2025, 15:21
Dinesh Pendharkar: Honored to be Featured in ET Panache, The Times Of India
Voices
Aug 15, 2025, 15:13
Announcing the new Global Oncology Fellowship Program - PM Global Cancer
Blog Posts
Aug 15, 2025, 15:10
Global Palliative Care Research Trends and Gaps (2013–2022) - Ecancer
Insight
Aug 15, 2025, 15:10
Gerry Hanna: Benefit of Hippocampal Avoidance in Whole Brain RT
Career Updates
Aug 15, 2025, 15:08
Ruben Mesa is Starting a New Position as President, Cancer National Service Line at Advocate Health
Insight
Aug 15, 2025, 15:06
Monica Shaw: Bristol Myers Squibb and Advocate Health Care to Expand Clinical Trial Access
Voices
Aug 15, 2025, 15:06
Harold J. Burstein։ Big Year for Long-Term Endocrine Therapy in Breast Cancer
Voices
Aug 15, 2025, 14:53
Michael Camit: Key Takeaways of NSW Cancer Summit 2025
New Paper Alert
Aug 15, 2025, 14:50
New Paper Alert: BRCA1/2 Mutations and RB1 Alterations Predict Poorer Outcomes With Endocrine Therapy ± CDK4/6 Inhibitors in HR+/HER2– Breast Cancer
Insight
Aug 15, 2025, 14:48
Mark Roschewski: Precise Remission Assessment in LBCL Using PhasED-Seq ctDNA
Insight
Aug 15, 2025, 14:42
Kenji López-Cuevas: $27K Medicine Donation from Cancer Warriors Foundation of Mexico